Jan. 20, 2021
Erica Lizano, assistant professor of social work
Cal State Fullerton faculty recently published research and were honored for their work on a variety of subjects from wet markets and adolescent snack choices to publication design and the alcohol immigrant paradox. These are the items submitted during December 2020.
PUBLICATIONS
Gordon Capp, assistant professor of social work, co-authored “Exploring Patterns of Positive and Negative School Climate Experiences Among Staff Members in California” in the Journal of School Violence.
Brittany Eghaneyan, assistant professor of social work, co-authored “Hispanic Participants in the National Institute on Drug Abuse’s Clinical Trials Network: A Scoping Review of Two Decades of Research” in Addictive Behaviors Reports.
UpdatedTue, Jan 19, 2021 at 12:04 am ET
Reply
Recent research from the National Institute on Drug Abuse (NIDA) indicates a team-based approach to the treatment of Opioid Use Disorder (OUD) may improve buprenorphine care. A collaborative approach to treating opioid use disorder that relies heavily on community pharmacists is feasible and may increase adherence and participant satisfaction, according to the study as part of the National Institutes of Health, through the NIDA Center for the Clinical Trials Network.
Most people with OUD who would benefit from medication do not receive it. Buprenorphine is a safe and effective medication that has been used in opioid addiction treatment for nearly two decades, but providers must complete training and receive a special waiver in order to prescribe buprenorphine to treat opioid use disorder. In the United States, fewer than 10% of primary care providers are authorized to prescribe buprenorphine, and more than 20 million people in the Unit
Credit: UT Southwestern Medical Center
DALLAS - Jan. 13, 2021 - A new treatment that combines two existing medications may provide long-sought relief for many battling debilitating methamphetamine use disorder, according to a study to be published tomorrow in
The article, based on a multisite study funded by the National Institutes of Health (NIH), describes how combining an injectable drug currently used to treat alcohol and opioid addictions (naltrexone), and a commonly prescribed antidepressant (bupropion) produced positive results in 13.6 percent of the 403 patients treated, significantly higher than the 2.5 percent response in placebo groups. This is an important advance given that there are now no effective treatments for methamphetamine use disorder, says Madhukar Trivedi, M.D., a UT Southwestern professor of psychiatry and first author of the study.
have been provided with the technical expertise of ViiV Healthcare and a financial incentive from Unitaid via CHAI, to accelerate the development, registration, manufacture and supply of generic. | January 15, 2021